Patents by Inventor Ulrik Morch

Ulrik Morch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9447185
    Abstract: The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: September 20, 2016
    Assignees: INNATE PHARMA, S.A., UNIVERSITY OF GENOVA, NOVO NORDISK A/S
    Inventors: Francois Romagne, Alessandro Moretta, Mathieu Blery, Petrus Johannes Louis Spee, Ulrik Morch
  • Publication number: 20080274047
    Abstract: The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.
    Type: Application
    Filed: October 13, 2006
    Publication date: November 6, 2008
    Applicants: INNATE PHARMA, UNIVERSITA DI GENOVA, NOVO NORDISK A/S
    Inventors: Francois Romagne, Alessandro Moretta, Mathieu Blery, Petrus Johannes Louis Spee, Ulrik Morch
  • Publication number: 20050180967
    Abstract: A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder, or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector.
    Type: Application
    Filed: January 28, 2005
    Publication date: August 18, 2005
    Applicant: Symphogen A/S
    Inventors: John Haurum, Kirsten Drejer, Ulrik Morch